PHARMACEUTICAL 2026

ELI Lilly Co
Rank 98 of 178



PHARMACEUTICAL 2026

ELI Lilly Co
Rank 98 of 178

The relative strengths and weaknesses of ELI Lilly Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI Lilly Co compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 73% points.The greatest weakness of ELI Lilly Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 90% points.

The company's Economic Capital Ratio, given in the ranking table, is 214%, being 15% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	55,629,000
Cost of Goods Sold	11,052,000
Intangible Assets	12,419,000
Liabilities, Current	35,228,000
Liabilities, Non-Current	50,713,000
Other Assets	19,753,000
Other Compr. Net Income	1,442,000
Other Expenses	6,146,000
Other Liabilities	0
Other Net Income	0
Other Revenues	65,179,000
Property and Equipment	24,675,000
Research and Development	16,247,000
Selling, General and Administrative Expense	11,094,000

Output Variable	Value in 1000 USD
Assets	112,476,000
Liabilities	85,941,000
Expenses	44,539,000
Revenues	65,179,000
Stockholders Equity	26,535,000
Net Income	20,640,000
Comprehensive Net Income	21,361,000
BaseVar	154,788,500
ECR before LimitedLiability	80%
Economic Capital Ratio	214%